Biosimilar Competitive Positioning Beyond the Named Leaders

Mapping the Share Nobody Names: A Biosimilar Competitive Positioning Strategy for a Mid-Tier Manufacturer

Case Study: Building a Biosimilar Competitive Positioning Strategy Against the Right Peer Set

A privately held specialty biologics manufacturer headquartered in Ireland, with an immunology and supportive-oncology biosimilar portfolio sold into European hospital tenders and no United States filing, engaged Cognitive Market Research and Consulting after its board rejected two consecutive strategic plans. Both plans had benchmarked the company against the largest named participants in the category and concluded it was structurally outmatched. The company's difficulty was not that the conclusion was wrong but that the comparison was: the five participants it measured itself against hold roughly a fifth of the market between them, and the company had never established who holds the rest.

Introduction

The global biologics and biosimilars market stood at USD 487.0 billion in 2025 and USD 534.3 billion in 2026, advancing at a 9.8% CAGR toward USD 1,243.8 billion by 2035, with biosimilars leading growth as monoclonal antibodies and insulin variants gain share among cost-conscious healthcare systems. Yet the named competitive set in this category accounts for a minority of that value. Pfizer Inc. holds 11.4% globally, Amgen Inc. 7.2%, Sandoz Group AG 2.2%, Samsung Bioepis Co., Ltd. 0.5% and Biocon Biologics Limited 0.3% to  21.6% combined, leaving 78.4% distributed across participants no competitive review had profiled.

However, the organization lacked clarity on:

• Molecule Overlap With Named Portfolios Unquantified: The client's immunology and supportive-oncology lines sit directly against Sandoz Group AG's Hyrimoz, Pyzchiva and Omnitrope portfolios and Amgen Inc.'s Enbrel, Prolia, Repatha and WEZLANA lines, while adjacent pools, anti-VEGF ophthalmic solutions and recombinant human insulins, where Samsung Bioepis and Biocon Biologics hold the only named positions at 0.5% and 0.3% had never been sized as entry options. The company was competing hardest where the named leaders are strongest and had not costed the alternative.
• Global Share Ambition That Is Really A United States Ambition: The United States alone accounts for USD 238.0 billion of the 2026 market, a 44.5% share, with 65% of physicians choosing biosimilars over reference products and 75% of payers running cost-containment programs. With no United States filing, roughly 44.5% of the market was closed to the client by absence rather than by competition, yet its plans read its low global share as commercial weakness in the markets it does serve.
• Tender Award Mechanics Mistaken For A Pricing Problem: The client had been losing European hospital business and treating it as a price gap. Italy awards through multi-winner regional tenders with 67% institutional adoption preference and appeals exposure, Germany runs slow centralized cycles under statutory pricing caps, the United Kingdom concentrates purchasing through national frameworks with 66% of NHS trusts on best-value policies, and France applies health technology assessment with 68% value-based integration. Four award mechanics were being answered with one discount.
• R&D Intensity Benchmarked Against The Wrong Group: Measuring itself against Pfizer Inc., which invests USD 11.00 billion against USD 61.00 billion of revenue, the client had concluded it was underinvesting at its own ratio. The comparator group it actually competes with spends differently — Sandoz Group AG at USD 900 million on USD 12.00 billion, Samsung Bioepis at USD 250 million on USD 1.80 billion, Biocon Biologics at USD 150 million on USD 1.20 billion — and the correct benchmark changed the investment conclusion entirely.

Every one of these gaps traced to the same root: a competitive picture built only from the participants large enough to be named, in a market where those participants hold 21.6%.

Solution

Cognitive Market Research and Consulting delivered a customized, data-driven market entry and portfolio optimization framework. Because the diagnosis centred on a fragmented competitive structure inside a heavily regulated, tender-driven market, the analytical weight went to category segmentation and competitive benchmarking, with distribution work scoped to the tender mechanics that decide access and regional work scoped to the share concentration that frames the opportunity.

1. Global Market Segmentation & Category Sizing

The engagement rebuilt the category from the 2025 base through the 2035 horizon and cut it by therapeutic pool and molecule class, so the client's positioning decision referenced the pools it could realistically contest rather than the market total.Global biologics and biosimilars market size build-up in USD billion, 2025 actual to 2035 forecast at a 9.8% CAGR

• By Product Type / Segment: Monoclonal antibodies, fusion proteins, recombinant human insulins, anti-VEGF ophthalmic solutions and targeted cell therapies were sized separately, with the named participants' portfolio positions mapped onto each so the client could see which molecule classes are already contested by a named leader and which are not.
• By Application & End-User: Therapeutic pools were sized per country against the published splits — oncology at 45% of United States utilization, 42% in the United Kingdom, 40% in France and Brazil, 38% in Italy, with immunology at 30% in the United States and 32% in Italy, diabetes between 15% and 25%, and rare or specialized indications at 10% in most markets — establishing where the client's immunology weighting is an advantage and where it is a ceiling.
• Benchmarking & Projections: The trajectory from USD 487.0 billion in 2025 to USD 534.3 billion in 2026 and USD 1,243.8 billion by 2035 was decomposed by therapeutic pool, giving the client a model it could re-run as interchangeability and patent-expiry assumptions moved.

2. Regional & Country-Level Deep-Dives

Regional analysis was scoped to a single question the client had never posed directly: how much of its apparent share weakness is competitive and how much is simply geographic absence.

Top country markets in 2026 by value in USD billion with global share shown for each

• United States: At USD 238.0 billion and a 44.5% share, the single market the client does not serve is larger than the next five combined. Expanding interchangeability pathways and clear FDA approval tracks support entry, while patent thickets and litigation delay set the cost of it a, trade the client had never priced.
• Europe: Germany at USD 37.1 billion, France at USD 26.5 billion, the United Kingdom at USD 21.1 billion and Italy at USD 21.1 billion together form the client's served base. Automatic substitution guidelines in Germany and high biosimilar penetration across the bloc favour the client's position; statutory price caps and fragmented regional budgets constrain what that position earns.
• Asia Pacific & Americas: China at USD 66.0 billion and a 12% share runs on nationally tender-listed formulations preferred by 60% of regional hospitals, Japan at USD 31.5 billion carries low clinician familiarity with non-originator proteins, and Brazil at USD 16.0 billion, Canada at USD 15.9 billion and India at USD 13.9 billion each turn on a distinct access mechanism rather than on price.

3. Omnichannel Distribution Strategy

Distribution work addressed the structural error directly: four national award mechanics had been answered with a single commercial response, and no discount can fix a tender the client is structurally ineligible to win.

• Digital Commerce Tracking: Institutional procurement pathways were separated from clinician-led specification across each served market, isolating where purchasing decisions are made centrally, where they sit with regional authorities and where clinician trust still governs, Japan being the clearest case of the last.
• Offline Retail Performance: Award mechanics were modelled per country: Italy's multi-winner regional model with its legal appeals exposure, Germany's centralized hospital tender cycles under statutory caps, the United Kingdom's national frameworks and data-driven switching programs, France's health technology assessment gate, and Canada's provincial mandatory switching reaching 65% of the market.
• Channel Integration Playbooks: A bid architecture was built per award type rather than per country, with cold-chain and temperature-traceability commitments positioned as qualification criteria rather than cost lines, addressing the supply-chain volatility that constrains access in Brazil's remote regions and across Canadian winter distribution.

4. Competitive Landscape Benchmarking

Benchmarking replaced the named-participant list with a structural map of who actually holds the market, then re-based the client's investment benchmarks against the group it competes with.

Named participants against the rest of the market, showing 21.6% held by the five named and 78.4% outside them

• Market Share & Financial Analysis: The five named participants were profiled on revenue, R&D commitment and portfolio concentration — Pfizer Inc. at USD 61.00 billion revenue and 11.4% share, Amgen Inc. at USD 38.80 billion and 7.2%, Sandoz Group AG at USD 12.00 billion and 2.2%, Samsung Bioepis Co., Ltd. at USD 1.80 billion and 0.5%, Biocon Biologics Limited at USD 1.20 billion and 0.3% — and the 78.4% outside them was segmented by participant type rather than left as residual.
• Innovation & Deal Tracking: R&D intensity was recalculated against the relevant comparator group: Pfizer Inc. invests 18.0% of revenue, Amgen Inc. 10.8%, Sandoz Group AG 7.5%, Samsung Bioepis 13.9% and Biocon Biologics 12.5%. Against the specialty group rather than the originator group, the client's commitment was reframed from deficient to appropriately scaled, releasing the board's objection to the prior plans.
• Branding Strategy: Positioning was compared on the attributes that decide tender-led biosimilar selection interchangeability data depth, comparability evidence, supply reliability and cold-chain assurance, rather than on the novel-molecule messaging that dominates how the integrated originators present themselves.

Industry Impact

This engagement reflects broader structural shifts transforming the global landscape:

Named Share Is Not Market Structure: With 21.6% held across the five largest named participants, competitive reviews built only from recognisable names describe a minority of this category and systematically misread where contestable share sits.
Access Mechanics Are Displacing Price As The Decision Variable: Multi-winner regional tenders, centralized national frameworks, health technology assessment gates and provincial switching mandates each select on different criteria, making bid architecture a strategic capability rather than a commercial function.
Interchangeability Data Is Becoming The Entry Cost: Expanding interchangeability pathways and rising demand for clinical comparability evidence are shifting the barrier to entry from manufacturing capability toward evidence generation.
Cold-Chain Assurance Is Entering The Qualification Criteria: Blockchain-enabled temperature traceability and supply-chain integration are moving from operational overhead toward a condition of institutional eligibility, particularly in geographically dispersed markets.

How the biologics and biosimilars market adds value between 2025, 2026 and 2035 in USD billion

Cognitive Market Research and Consulting Role

Cognitive Market Research played a crucial strategic role in enabling the client's international expansion. We:

• Quantified and Segmented the global addressable market from a USD 487.0 billion 2025 base to a USD 1,243.8 billion 2035 forecast, split by molecule class, therapeutic pool and country market.
• Executed Comprehensive Regional Assessments across the ten largest country markets, separating geographic absence from competitive weakness in the client's share position.
• Constructed Distribution Models detailing award mechanics per country, with a bid architecture built by tender type and cold-chain assurance positioned as a qualification criterion.
• Evaluated Competitor Movements by profiling the five named participants on share, revenue and R&D intensity, and segmenting the 78.4% of the market held outside them.
• Delivered a Scalable Framework translating the full dataset into a positioning and entry plan the client's commercial, regulatory and evidence-generation teams could execute against and re-run annually.

Client Benefits

The engagement delivered highly actionable strategic and operational outcomes:

• Validated Expansion Strategies: A United States filing was costed against the 44.5% share it unlocks and the litigation delay it carries, converting the largest single question in the client's plan from an assumption into a decision with a price attached.
• Optimized Channel Performance: Bids were rebuilt per award mechanic rather than per country, addressing the structural eligibility gap that discounting had been failing to close across Italy, Germany, the United Kingdom and France.
• Data-Backed Product Innovation: Portfolio investment shifted toward molecule classes where no named participant holds an established position, with anti-VEGF ophthalmic and recombinant insulin pools entered on evidence rather than on adjacency.
• Strengthened Competitive Position: Re-basing R&D intensity against the specialty group at 7.5% to 13.9% of revenue, rather than against Pfizer Inc. at 18.0%, resolved the board objection that had blocked two prior plans.
• Reduced Investment Risk: Markets selecting on clinician familiarity rather than price Japan most clearly were deprioritised for this cycle, with capital redirected toward the award mechanics the client can satisfy now.

Conclusion

By replacing a list of recognisable competitors with a structural map of who holds the market, Cognitive Market Research and Consulting turned a plan the board had twice rejected into one it could approve. The resulting biosimilar competitive positioning strategy established that the five named participants hold 21.6% of a USD 534.3 billion market, that 78.4% sits outside them, and that the client's apparent share weakness was substantially geographic absence from a United States market worth USD 238.0 billion rather than competitive failure in the markets it serves. The framework is built to be re-run as the category advances toward USD 1,243.8 billion by 2035, so interchangeability and award-mechanic assumptions can be refreshed rather than rebuilt. Multi-year data support keeps that spine current, giving each planning cycle an updated evidence base instead of a fresh set of assumptions.